Merck dives deeper into KRAS, teaming up with Taiho, Astex to develop small molecule drugs
As the race — led by Amgen — to subdue the notorious KRAS oncogene heats up in the early clinical space, Merck has decided it’s not enough …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
